New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy

  • Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[1]
     
  • ADMYRA data reinforces review summarizing 90+ publications, that switching from reference …
/by